Acknowledgement
This work was supported by the Ewha Womans University Research Grant of 2023 (1-2023-0406-001-1) and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (RS-2024-00336028).
References
- Pavlova NN and Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23, 27-47
- Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12, 31-46
- Schiwitza A, Schildhaus HU, Zwerger B et al (2019) Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Immunotherapy 11, 769-782
- Atkins MB and Tannir NM (2018) Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev 70, 127-137
- De Re V, Caggiari L, Repetto O, Mussolin L and Mascarin M (2019) Classical Hodgkin's lymphoma in the era of immune checkpoint inhibition. J Clin Med 8, 1596
- Han Y, Liu D and Li L (2020) PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10, 727-742
- Morad G, Helmink BA, Sharma P and Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309-5337
- Conroy M and Naidoo J (2022) Immune-related adverse events and the balancing act of immunotherapy. Nat Commun 13, 392
- Xia L, Oyang L, Lin J et al (2021) The cancer metabolic reprogramming and immune response. Mol Cancer 20, 28
- Cong J, Wang X, Zheng X et al (2018) Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression. Cell Metab 28, 243-255 e245
- Ho PC, Bihuniak JD, Macintyre AN et al (2015) Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217-1228
- Spence AM, Muzi M, Graham MM et al (2002) 2-[(18)F] Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res 8, 971-979
- Guo H, Nan Y, Zhen Y et al (2016) miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1. Tumour Biol 37, 13751-13761
- Won WJ, Deshane JS, Leavenworth JW, Oliva CR and Griguer CE (2019) Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma. Cell Stress 3, 47-65
- Raber P, Ochoa AC and Rodriguez PC (2012) Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 41, 614-634
- Brand A, Singer K, Koehl GE et al (2016) LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 24, 657-671
- Watson MJ, Vignali PDA, Mullett SJ et al (2021) Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 591, 645-651
- Feng Q, Liu Z, Yu X et al (2022) Lactate increases stem-ness of CD8 + T cells to augment anti-tumor immunity. Nat Commun 13, 4981
- Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E and Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11, 312-319
- Opitz CA, Litzenburger UM, Sahm F et al (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197-203
- Uyttenhove C, Pilotte L, Theate I et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9, 1269-1274
- Pilotte L, Larrieu P, Stroobant V et al (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3- dioxygenase. Proc Natl Acad Sci U S A 109, 2497-2502
- Pallett LJ, Dimeloe S, Sinclair LV, Byrne AJ and Schurich A (2021) A glutamine 'tug-of-war': targets to manipulate glutamine metabolism for cancer immunotherapy. Immunother Adv 1, ltab010
- Altman BJ, Stine ZE and Dang CV (2016) From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer 16, 619-634
- Liu Y, Yang L, An H et al (2015) High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma. Sci Rep 5, 16954
- Lu J, Chen M, Tao Z et al (2017) Effects of targeting SLC1A5 on inhibiting gastric cancer growth and tumor development in vitro and in vivo. Oncotarget 8, 76458-76467
- Guerra L, Bonetti L and Brenner D (2020) Metabolic modulation of immunity: a new concept in cancer immunotherapy. Cell Rep 32, 107848
- Guo C, You Z, Shi H et al (2023) SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature 620, 200-208
- Chen CL, Hsu SC, Ann DK, Yen Y and Kung HJ (2021) Arginine signaling and cancer metabolism. Cancers (Basel) 13, 3541
- Rath M, Muller I, Kropf P, Closs EI and Munder M (2014) Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol 5, 532
- Sun N and Zhao X (2022) Argininosuccinate synthase 1, arginine deprivation therapy and cancer management. Front Pharmacol 13, 935553
- Marti ILAA and Reith W (2021) Arginine-dependent immune responses. Cell Mol Life Sci 78, 5303-5324
- Geiger R, Rieckmann JC, Wolf T et al (2016) L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829-842 e813
- Lamas B, Vergnaud-Gauduchon J, Goncalves-Mendes N et al (2012) Altered functions of natural killer cells in response to L-arginine availability. Cell Immunol 280, 182-190
- Guerrero-Rodriguez SL, Mata-Cruz C, Perez-Tapia SM and Velasco-Velazquez MA (2022) Role of CD36 in cancer progression, stemness, and targeting. Front Cell Dev Biol 10, 1079076
- Feng WW, Wilkins O, Bang S et al (2019) CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies. Cell Rep 29, 3405-3420 e3405
- Ladanyi A, Mukherjee A, Kenny HA et al (2018) Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene 37, 2285-2301
- Gharpure KM, Pradeep S, Sans M et al (2018) FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9, 2923
- Mukherjee A, Chiang CY, Daifotis HA et al (2020) Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance. Cancer Res 80, 1748-1761
- Nieman KM, Kenny HA, Penicka CV et al (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17, 1498-1503
- Zhu G, Guo N, Yong Y, Xiong Y and Tong Q (2019) Effect of 2-deoxy-D-glucose on gellan gum biosynthesis by Sphingomonas paucimobilis. Bioprocess Biosyst Eng 42, 897-900
- Dey S, Murmu N, Mondal T et al (2022) Multifaceted entrancing role of glucose and its analogue, 2-deoxy-Dglucose in cancer cell proliferation, inflammation, and virus infection. Biomed Pharmacother 156, 113801
- Sasawatari S, Okamoto Y, Kumanogoh A and Toyofuku T (2020) Blockade of N-glycosylation promotes antitumor immune response of T cells. J Immunol 204, 1373-1385
- Liu Y, Cao Y, Zhang W et al (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11, 1672-1682
- Siebeneicher H, Cleve A, Rehwinkel H et al (2016) Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876. ChemMedChem 11, 2261-2271
- Oshima N, Ishida R, Kishimoto S et al (2020) Dynamic imaging of LDH inhibition in tumors reveals rapid in vivo metabolic rewiring and vulnerability to combination therapy. Cell Rep 30, 1798-1810 e1794
- Granchi C, Roy S, Giacomelli C et al (2011) Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem 54, 1599-1612
- Maftouh M, Avan A, Sciarrillo R et al (2014) Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer 110, 172-182
- Payen VL, Mina E, Van Hee VF, Porporato PE and Sonveaux P (2020) Monocarboxylate transporters in cancer. Mol Metab 33, 48-66
- Kober C, Roewe J, Schmees N et al (2023) Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy. J Immunother Cancer 11, e007495
- Reinfeld BI, Madden MZ, Wolf MM et al (2021) Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282-288
- Schulte ML, Fu A, Zhao P et al (2018) Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med 24, 194-202
- Ma H, Wu Z, Peng J et al (2018) Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab. Int J Cancer 142, 2578-2588
- Nachef M, Ali AK, Almutairi SM and Lee SH (2021) Targeting SLC1A5 and SLC3A2/SLC7A5 as a potential strategy to strengthen anti-tumor immunity in the tumor microenvironment. Front Immunol 12, 624324
- Leone RD, Zhao L, Englert JM et al (2019) Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science 366, 1013-1021
- Oh MH, Sun IH, Zhao L et al (2020) Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest 130, 3865-3884
- Edwards DN, Ngwa VM, Raybuck AL et al (2021) Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest 131, e140100
- Kuzu OF, Noory MA and Robertson GP (2016) The role of cholesterol in cancer. Cancer Res 76, 2063-2070
- Nomura M, Liu J, Rovira II et al (2016) Fatty acid oxidation in macrophage polarization. Nat Immunol 17, 216-217
- Batista-Gonzalez A, Vidal R, Criollo A and Carreno LJ (2019) New insights on the role of lipid metabolism in the metabolic reprogramming of macrophages. Front Immunol 10, 2993
- Wang Z, Aguilar EG, Luna JI et al (2019) Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 25, 141-151
- Qiu J, Villa M, Sanin DE et al (2019) Acetate promotes T cell effector function during glucose restriction. Cell Rep 27, 2063-2074.e5
- Wu J, Li G, Li L, Li D, Dong Z and Jiang P (2021) Asparagine enhances LCK signalling to potentiate CD8(+) T-cell activation and anti-tumour responses. Nat Cell Biol 23, 75-86
- Wang T, Gnanaprakasam JNR, Chen X et al (2020) Inosine is an alternative carbon source for CD8(+)-T-cell function under glucose restriction. Nat Metab 2, 635-647
- Amitrano AM and Kim M (2023) Metabolic challenges in anticancer CD8 T cell functions. Immune Netw 23, e9
- Triozzi PL, Stirling ER, Song Q et al (2022) Circulating immune bioenergetic, metabolic, and genetic signatures predict melanoma patients' response to anti-PD-1 immune checkpoint blockade. Clin Cancer Res 28, 1192-1202
- Varghese S, Pramanik S, Williams LJ et al (2021) The glutaminase inhibitor CB-839 (Telaglenastat) enhances the antimelanoma activity of T-cell-mediated immunotherapies. Mol Cancer Ther 20, 500-511
- Ma X, Xiao L, Liu L et al (2021) CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability. Cell Metab 33, 1001-1012
- Lin R, Zhang H, Yuan Y et al (2020) Fatty acid oxidation controls CD8(+) tissue-resident memory T-cell survival in gastric adenocarcinoma. Cancer Immunol Res 8, 479-492
- Lim SA, Wei J, Nguyen TM et al (2021) Lipid signalling enforces functional specialization of T(reg) cells in tumours. Nature 591, 306-311
- Scharping NE, Menk AV, Whetstone RD, Zeng X and Delgoffe GM (2017) Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res 5, 9-16
- Afzal MZ, Mercado RR and Shirai K (2018) Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. J Immunother Cancer 6, 64
- Afzal MZ, Dragnev K, Sarwar T and Shirai K (2019) Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. Lung Cancer Manag 8, LMT11
- Kansal V, Burnham AJ, Kinney BLC et al (2023) Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. J Immunother Cancer 11, e005940
- Zhang Y, Kurupati R, Liu L et al (2017) Enhancing CD8(+) T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell 32, 377-391.e9
- Chowdhury PS, Chamoto K, Kumar A and Honjo T (2018) PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8(+) T cells and facilitates anti-PD-1 therapy. Cancer Immunol Res 6, 1375-1387
- Schlaepfer IR and Joshi M (2020) CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential. Endocrinology 161, bqz046
- Chamoto K, Chowdhury PS, Kumar A et al (2017) Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci U S A 114, E761-E770
- Yang W, Bai Y, Xiong Y et al (2016) Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature 531, 651-655
- Sun X, Fan T, Sun G et al (2022) 2-Deoxy-D-glucose increases the sensitivity of glioblastoma cells to BCNU through the regulation of glycolysis, ROS and ERS pathways: in vitro and in vivo validation. Biochem Pharmacol 199, 115029
- Chan DA, Sutphin PD, Nguyen P et al (2011) Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 3, 94ra70
- Guo L, Zhang W, Xie Y et al (2022) Diaminobutoxysubstituted isoflavonoid (DBI-1) enhances the therapeutic efficacy of GLUT1 inhibitor BAY-876 by modulating metabolic pathways in colon cancer cells. Mol Cancer Ther 21, 740-750
- Picard LK, Littwitz-Salomon E, Waldmann H and Watzl C (2022) Inhibition of glucose uptake blocks proliferation but not cytotoxic activity of NK cells. Cells 11, 3489
- Reckzeh ES, Karageorgis G, Schwalfenberg M et al (2019) Inhibition of glucose transporters and glutaminase synergistically impairs tumor cell growth. Cell Chem Biol 26, 1214-1228.e25
- Polanski R, Hodgkinson CL, Fusi A et al (2014) Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res 20, 926-937
- Panfili E, Mondanelli G, Orabona C et al (2023) The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1. Front Immunol 14, 1134551
- Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL and Townsend CA (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 97, 3450-3454
- Lemberg KM, Gori SS, Tsukamoto T, Rais R and Slusher BS (2022) Clinical development of metabolic inhibitors for oncology. J Clin Invest 132, e148550
- Ruiz-Perez MV, Sainero-Alcolado L, Oliynyk G et al (2021) Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma. iScience 24, 102128
- Feng J, Dai W, Mao Y et al (2020) Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1alpha/PPAR-gamma/PKM2-mediated glycolysis. J Exp Clin Cancer Res 39, 24